Building the Blueprint for Scientific Discovery
Aligning Discoveries Across Psychedelic Therapies (ADAPT) brings together a consortium of researchers to create a robust, transparent, and collaborative psychedelic research ecosystem that advances discovery and therapeutic potential.
Structuring the Science of Psychedelics
Why Now?
Much attention has been given to the potential of psychedelics to treat a variety of neuropsychiatric conditions including post-traumatic stress disorder, depression, and addiction. However, much remains unknown about how these substances work, how to measure behavioral and biological effects, and who is most likely to benefit from them therapeutically.
Our Plan of Action
Aligning Discoveries Across Psychedelic Therapies (ADAPT) brings together a consortium of researchers to establish validated tools and methods that reliably measure the behavioral and biological effects of psychedelics. By establishing robust and independently validated research methods, we aim to understand when and for whom psychedelics have therapeutic benefits, uncover psychedelics’ mechanisms, and lay the groundwork for responsible, evidence-based therapies. Learn more.
ADAPT’s Research Focus
ADAPT’s research program is structured around two workstreams that will develop validated tools and methods to reliably measure the effects of psychedelics, initially focusing on psilocybin in both preclinical and human studies.
By designing and testing rigorous methods, ADAPT’s consortium of researchers is creating standardized protocols to serve as a foundation for current and future research.
Independent Validation
Using a consortium model, multiple independent groups will replicate and expand upon findings underpinning commonly cited psychedelic studies.
Method Development and Optimization
This work will establish new and better ways to measure the effects of psychedelics, including behavioral measures (e.g., creative thinking, rumination, autobiographical memory) and biological and neural measures (e.g., brain activity), to inform clinical trial design.